Sputnik V test batch manufactured by Morepen Laboratories in India
Sputnik V was granted an emergency use authorization in the country on April 12, 2021
A test batch of Sputnik V coronavirus vaccine was manufactured by Morepen Laboratories in India, the Russian Direct Investment Fund (RDIF) said on Tuesday.
"The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Morepen Laboratories, one of the leading manufacturers of pharmaceutical products in India, today announced the production of the test batch of the Russian Sputnik V coronavirus vaccine in an exclusive facility in the state of Himachal Pradesh (HP). The first batch will be shipped to the Gamaleya Center for quality control. RDIF and Morepen Laboratories signed a cooperation agreement in June 2021 and are actively implementing the technology transfer," the statement said.
"As the pandemic is yet far from over and new, more dangerous variants of coronavirus are being detected in various regions of the world, RDIF is increasing capacities for the production of Sputnik V in India, one of the key hubs. Agreement with Morepen Laboratories provides for a larger amount of Sputnik V to be available both for India and our partners globally to speed up the vaccination with one of the best vaccines in the world," CEO of the Russian Direct Investment Fund Kirill Dmitriev commented.
"We are delighted to partner with RDIF for the prestigious project of Sputnik V production in India. This would be our privilege to work jointly on expanding the production base in India. We take this partnership as a starting point for a long term relationship with RDIF and its partner companies as we look forward to many more areas of common interest. Morepen’s commitment towards this project is a step forward towards entry into biosimilars and other biologicals," Chairman & Managing Director of Morepen Laboratories Limited Sushil Suri said.
According to the press release, Sputnik V was granted an emergency use authorization in India on April 12, 2021. India is the leading production hub for Sputnik V. RDIF had reached agreements earlier with other leading pharmaceutical companies in India - Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech. In total, agreements with partners in India provide for the production of more than 850 mln doses of Sputnik V per year.
About the vaccine
To date, Sputnik V has been registered in 67 countries globally with a total population of over 3.5 bln people. The data obtained by regulators of a number of countries during the vaccination of the population, including Argentina, Serbia, Bahrain, Hungary, Mexico and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.
"Sputnik V is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots," RDIF said.
COVID-19 outbreak
In late December 2019, Chinese officials informed the World Health Organization (WHO) about the outbreak of previously unknown pneumonia in the city of Wuhan, in central China. Since then, cases of the novel coronavirus - named COVID-19 by the WHO - have been reported in every corner of the globe, including Russia. On March 11, 2020, the WHO declared the coronavirus outbreak a pandemic.
Source: Tass
Read more from the below TAGS
People also reading-
